The advanced nature of metastatic disease at the time of diagnosis in November 2023, the unfavorable prognosis of the disease, and resistance to immunotherapy and targeted molecular therapy in the presence of a likely pathogenic FANCI variant in the patient support the possible disease-modifying role of the FANCI gene in patients with malignant melanoma (Table 1). The gene discussed is FANCI; the disease is metastatic neoplasm.